STABILIZATION OF POLIOVIRUS INFECTIVITY TO LYOPHILIZATION

口服脊髓灰质炎病毒疫苗(OPV)在不接种时会迅速失效 保持在冻结状态。将口服脊髓灰质炎疫苗稳定在较宽松的水平 储存条件将极大地促进脊髓灰质炎病毒的免疫 程序。有些疫苗可以冷冻干燥并储存在固态中， 但冷冻干燥后，脊髓灰质炎病毒的传染性大大降低。 我们已经系统地评估了不同的条件和添加剂在 寻找一种可以成功进行冷冻干燥的程序 脊髓灰质炎病毒。用两种酶联免疫吸附试验对冻干材料进行检测 D抗原和感染病毒的空斑试验。夸张的 使用一种脂类可以提高病毒存活率 以试剂为基础，使病毒存活率增加1000，并导致 20-40%的病毒感染力在冻干后存活。尝试次数为 继续进一步提高病毒的稳定性，以进行冷冻干燥和 评价冻干制品的时间稳定性和温度稳定性 病毒。

Oral poliovirus vaccine (OPV) can rapidly lose potency when not maintained in a frozen state. Stabilization of OPV to less stringent storage conditions would greatly facilitate the poliovirus immunization program. Some vaccines can be lyophilized and stored in a solid state, but poliovirus infectivity is greatly diminished after lyophilization. We have systematically evaluated different conditions and additives in search of a procedure that would allow the successful lyophilization of poliovirus. Lyophilized material was assayed by both the Elisa assay for D antigen and for infectious virus by a plaque assay. Dramative improvements in viral survival were obtained with the use of a lipid based reagent, which increased viral survival by 1000 and resulted in 20-40% of the viral infectivity surviving lyophilization. Attempts are continuing to further increase virus stability to lyophilization and to evaluate the temporal and temperature stability of the lyophilized virus.